CBB. PFE has little interest IMHO in AMRN. Their focus is on their Covid vaccine and the likely additional booster we'll need this year . They are making plenty of $ with that and have no need for a Co with no patent protection in the US Your other picks ...Roche, Novo Nordisk , Merck . Roche ...no significant presence in the EU CV market Novo Nordisk and Merck ...some presence in Diabetes and Heart failure
None of these Co's have the EU exposure in CV drugs ...as NVS does with their marketing programs for Entresto and Inclisiran
Your PFE acquisition dream isn't going anywhere IMHO and since U insist on repeating the same posts over and over again I think I'll skip reading them for awhile